NASDAQ:OBLNObalon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Obalon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.67 +0.02 (+3.08 %) (As of 04/8/2020 01:09 AM ET) Add Compare Share Today's Range$0.66Now: $0.67▼$0.6950-Day Range$0.65MA: $1.12▼$1.9852-Week Range$0.62Now: $0.67▼$19.20Volume54,422 shsAverage Volume194,047 shsMarket Capitalization$5.18 millionP/E RatioN/ADividend YieldN/ABeta-1.87 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingObalon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Obalon Therapeutics has a potential upside of 1,765.7% from its current price of $0.67.Amount of Analyst CoverageObalon Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesObalon Therapeutics has received 245 “outperform” votes. (Add your “outperform” vote.)Underperform VotesObalon Therapeutics has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentObalon Therapeutics has received 51.87% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote “Outperform” if you believe OBLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldObalon Therapeutics does not currently pay a dividend.Dividend GrowthObalon Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Obalon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.30% of the stock of Obalon Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.33% of the stock of Obalon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Obalon Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Obalon Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioObalon Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBLN Previous Symbol CUSIPN/A CIK1427570 Webhttp://www.obalon.com/ Phone844-362-2566Debt Debt-to-Equity Ratio0.04 Current Ratio4.59 Quick Ratio4.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.28 million Price / Sales1.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book0.33Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-23,680,000.00 Net Margins-721.61% Return on Equity-186.35% Return on Assets-98.02%Miscellaneous Employees100 Outstanding Shares7,732,000Market Cap$5.18 million Next Earnings Date5/8/2020 (Estimated) OptionableOptionable Receive OBLN News and Ratings via Email Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OBLN Rates by TradingView Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions How has Obalon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OBLN stock has decreased by 35.6% and is now trading at $0.67. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Obalon Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Obalon Therapeutics. When is Obalon Therapeutics' next earnings date? Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Obalon Therapeutics. How were Obalon Therapeutics' earnings last quarter? Obalon Therapeutics Inc (NASDAQ:OBLN) announced its earnings results on Thursday, February, 27th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.06. The company had revenue of $0.79 million for the quarter. Obalon Therapeutics had a negative return on equity of 186.35% and a negative net margin of 721.61%. View Obalon Therapeutics' earnings history. When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work? Shares of Obalon Therapeutics reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for OBLN? 3 Wall Street analysts have issued 12-month price targets for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Obalon Therapeutics' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 1,765.7% from the stock's current price. View analysts' price targets for Obalon Therapeutics. Has Obalon Therapeutics been receiving favorable news coverage? News stories about OBLN stock have been trending very negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obalon Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutObalon Therapeutics. Who are some of Obalon Therapeutics' key competitors? Some companies that are related to Obalon Therapeutics include DarioHealth (DRIO), Interpace Diagnostics Group (IDXG), Motus GI (MOTS), Neovasc (NVCN), RA Medical Systems (RMED), Atossa Genetics (ATOS), Titan Medical (TMDI), Endologix (ELGX), Dynatronics (DYNT), Avinger (AVGR), Lianluo Smart (LLIT), Encision (ECIA), Hancock Jaffe Laboratories (HJLI), PlusTherapeuticsInc . (PSTV) and CELLECT BIOTECH/S (APOP). What other stocks do shareholders of Obalon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Opko Health (OPK), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Corbus Pharmaceuticals (CRBP), Inpixon (INPX), Onconova Therapeutics (ONTX) and Titan Pharmaceuticals (TTNP). Who are Obalon Therapeutics' key executives? Obalon Therapeutics' management team includes the following people: Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)Mr. William John Plovanic CFA, CFO & Sec. (Age 50)Mr. Mark C. Brister, Chief Technology Officer (Age 57)Ms. Daina Schmidt, VP of Marketing When did Obalon Therapeutics IPO? (OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager. What is Obalon Therapeutics' stock symbol? Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN." How do I buy shares of Obalon Therapeutics? Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Obalon Therapeutics' stock price today? One share of OBLN stock can currently be purchased for approximately $0.67. How big of a company is Obalon Therapeutics? Obalon Therapeutics has a market capitalization of $5.18 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe. View additional information about Obalon Therapeutics. What is Obalon Therapeutics' official website? The official website for Obalon Therapeutics is http://www.obalon.com/. How can I contact Obalon Therapeutics? Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Why does the United States have a lingering trade deficit?
